Suvretta Capital Management’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $35M | Buy |
5,082,900
+15,506
| +0.3% | +$107K | 1.05% | 30 |
|
|
2025
Q1 | $14.6M | Buy |
5,067,394
+1,728,928
| +52% | +$4.98M | 0.54% | 48 |
|
|
2024
Q4 | $15.7M | Buy |
3,338,466
+2,155,675
| +182% | +$10.1M | 0.53% | 47 |
|
|
2024
Q3 | $4.22M | Sell |
1,182,791
-1,358,255
| -53% | -$4.85M | 0.14% | 64 |
|
|
2024
Q2 | $15.8M | Sell |
2,541,046
-307,440
| -11% | -$1.91M | 0.58% | 42 |
|
|
2024
Q1 | $26.9M | Sell |
2,848,486
-2,670,395
| -48% | -$25.2M | 1% | 32 |
|
|
2023
Q4 | $37.3M | Sell |
5,518,881
-200,000
| -3% | -$1.35M | 1.68% | 21 |
|
|
2023
Q3 | $25.4M | Hold |
5,718,881
| – | – | 1.37% | 24 |
|
|
2023
Q2 | $18.9M | Buy |
5,718,881
+541,171
| +10% | +$1.79M | 1.01% | 35 |
|
|
2023
Q1 | $14.8M | Buy |
5,177,710
+902,907
| +21% | +$2.57M | 0.62% | 42 |
|
|
2022
Q4 | $31.1M | Buy |
4,274,803
+746,803
| +21% | +$5.44M | 1.31% | 31 |
|
|
2022
Q3 | $28.5M | Buy |
3,528,000
+172,376
| +5% | +$1.39M | 1.19% | 31 |
|
|
2022
Q2 | $16.4M | Buy |
3,355,624
+742,212
| +28% | +$3.64M | 0.63% | 49 |
|
|
2022
Q1 | $61.8M | Buy |
2,613,412
+237,841
| +10% | +$5.62M | 1.89% | 23 |
|
|
2021
Q4 | $42M | Buy |
2,375,571
+433,602
| +22% | +$7.67M | 0.81% | 35 |
|
|
2021
Q3 | $54.8M | Buy |
1,941,969
+314,525
| +19% | +$8.87M | 0.92% | 33 |
|
|
2021
Q2 | $17.1M | Buy |
1,627,444
+101,559
| +7% | +$1.06M | 0.26% | 64 |
|
|
2021
Q1 | $18M | Buy |
+1,525,885
| New | +$18M | 0.27% | 60 |
|